---
document_datetime: 2023-09-21 21:06:47
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/desloratadine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: desloratadine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.4258361
conversion_datetime: 2025-12-27 18:06:37.783723
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Desloratadine Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                             |
|----------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/962/ 202107    | Periodic Safety Update EU Single assessment - desloratadine                                               | 24/03/2022                          | 30/05/2022                                  | SmPC and PL                      | Please refer to Aerius-Azomyr-Neoclarityn-Desloratadine Teva-Dasselta-Desloratadine Actavis-Desloratadine ratiopharm-EMEA/H/C/PSUSA/00000962/202107 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IAIN/0028            | B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition | 26/07/2021                          | 30/05/2022                                  | SmPC, Labelling and              |                                                                                                                                                                                                                                                                     |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | of inks used for product marking - Changes in imprints, bossing or other markings                                                                                                                                                                                                                                                                                                                                                             |            |            | PL                    |           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------|
| IA/0027   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                 | 10/02/2021 | 30/04/2021 | Annex II and PL       |           |
| N/0026    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                              | 23/06/2020 | 30/04/2021 | PL                    |           |
| IB/0025   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                          | 15/04/2020 | 30/04/2021 | SmPC, Annex II and PL | the MAH   |
| IB/0023/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.c.z - Container closure system of the AS - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other | 13/02/2020 | n/a        |                       | variation |
| IA/0024   | B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other                                                                                                                                                                                                                                                                                                                                         | 16/01/2020 | n/a        |                       |           |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                  |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|
| N/0022    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/04/2019 | 30/04/2021 | Labelling and PL |
| IB/0021   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 02/07/2018 | n/a        |                  |
| N/0020    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/03/2018 | 12/12/2018 | PL               |
| IB/0018/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits | 07/03/2018 | n/a        |                  |

<div style=\"page-break-after: always\"></div>

|                   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS   |            |            |                        |                                                                                                                                          |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0019           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/01/2018 | 12/12/2018 | SmPC, Labelling and PL |                                                                                                                                          |
| N/0017            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 04/12/2017 | 12/12/2018 | PL                     |                                                                                                                                          |
| PSUSA/962/2 01607 | Periodic Safety Update EU Single assessment - desloratadine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/03/2017 | 24/05/2017 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/962/201607. |
| IB/0015/G         | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other                                                                                                                                                                                                                                                                                                            | 07/12/2016 | n/a        |                        |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| variation B.I.b.z - Change in control variation B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.III.2.a.1 - Change of non EU Pharmacopoeial with the Ph. Eur. or with a Member State - AS B.III.2.a.1 - Change of   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                                                                                                                                                                                                                                     |            |            |                        |                                                                                                                                                                                                                                                                                  |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0014    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                       | 23/06/2016 | 08/08/2016 |                        | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Desloratadine Teva in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0013/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites | 04/03/2016 | 12/05/2016 | Annex II and PL        |                                                                                                                                                                                                                                                                                  |
| IB/0012   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                  | 30/10/2015 | 12/05/2016 | SmPC, Annex II and PL  |                                                                                                                                                                                                                                                                                  |
| IB/0011   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                           | 28/08/2015 | 12/05/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0010   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/06/2015   | 12/05/2016   | SmPC, Labelling and PL           |         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|---------|
| IB/0009   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 05/05/2015   | 12/05/2016   | SmPC, Annex II, Labelling and PL | the MAH |
| IA/0008/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 17/02/2015   | n/a          |                                  |         |

<div style=\"page-break-after: always\"></div>

|           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                       |            |            |                        |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| T/0007    | Transfer of Marketing Authorisation from Teva Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). Authorisation                                                                                                                                                                                                                                          | 03/11/2014 | 01/12/2014 | SmPC, Labelling and PL | Transfer of Marketing |
| IA/0006/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size | 17/09/2014 | n/a        |                        |                       |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                   | 04/06/2014 | 01/12/2014 | PL                     |                       |
| IAIN/0004 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                     | 21/05/2013 | n/a        |                        |                       |
| IA/0003   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                      | 17/04/2013 | n/a        |                        |                       |
| N/0002    | Update of the local representatives contact details for Denmark.                                                                                                                                                                                                                                                                                   | 15/01/2013 | 01/12/2014 | PL                     |                       |

<div style=\"page-break-after: always\"></div>

|         | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0001 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation     | 02/07/2012 | 29/10/2012 | SmPC and PL | Correction of a typographical error in the tablet description in the SmPC and in the PIL for all the product information languages and update of the local representatives contact details for the United Kingdom, Italy and Ireland. The MAH also corrected the pharmaceutical form in the blister labelling for the Lithuanian text and amend the INN of Desloratadine in the Portuguese text. |